Inogen Stock Price, News & Analysis (NASDAQ:INGN) $5.81 +0.82 (+16.43%) (As of 12/7/2023 ET) Add Compare Share Share Today's Range$5.01▼$6.5650-Day Range$4.21▼$6.0352-Week Range$4.13▼$26.11Volume1.85 million shsAverage Volume320,758 shsMarket Capitalization$135.42 millionP/E RatioN/ADividend YieldN/APrice Target$13.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Inogen MarketRank™ Stock AnalysisAnalyst RatingReduce1.75 Rating ScoreUpside/Downside135.2% Upside$13.67 Price TargetShort InterestBearish6.65% of Shares Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment0.39Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.43) to ($2.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector428th out of 960 stocksSurgical Appliances & Supplies Industry14th out of 17 stocks 2.9 Analyst's Opinion Consensus RatingInogen has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.67, Inogen has a forecasted upside of 135.2% from its current price of $5.81.Amount of Analyst CoverageInogen has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.65% of the outstanding shares of Inogen have been sold short.Short Interest Ratio / Days to CoverInogen has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Inogen has recently increased by 51.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInogen does not currently pay a dividend.Dividend GrowthInogen does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInogen has received a 51.98% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Medical ventilators" product. See details.Environmental SustainabilityThe Environmental Impact score for Inogen is -1.12. Previous Next 3.0 News and Social Media Coverage News SentimentInogen has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Inogen this week, compared to 1 article on an average week.Search Interest2 people have searched for INGN on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Inogen to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inogen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.64% of the stock of Inogen is held by insiders.Percentage Held by Institutions93.15% of the stock of Inogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Inogen are expected to grow in the coming year, from ($3.43) to ($2.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inogen is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inogen is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInogen has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Inogen Stock (NASDAQ:INGN)Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; and related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.Read More INGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INGN Stock News HeadlinesDecember 8, 2023 | americanbankingnews.comInogen Sees Unusually High Options Volume (NASDAQ:INGN)December 7, 2023 | finanznachrichten.deAntea Group Sponsors 2024 AWS Global Water Stewardship Forum Through Inogen AllianceDecember 8, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. December 7, 2023 | finanznachrichten.deInogen Alliance: Resourcefulness in Evolving Global Solutions: Bi-Annual Meeting Insights From 2024December 7, 2023 | finance.yahoo.comInogen (INGN) Down 4.2% Since Last Earnings Report: Can It Rebound?November 30, 2023 | americanbankingnews.comShort Interest in Inogen, Inc. (NASDAQ:INGN) Grows By 52.0%November 14, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Inogen (INGN) and Celcuity (CELC)November 13, 2023 | finance.yahoo.comInogen Announces Leadership Change with the Appointment of Kevin Smith as President and CEODecember 8, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 10, 2023 | finance.yahoo.comInogen (INGN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesNovember 9, 2023 | finance.yahoo.comInogen to Present at Upcoming Investor Conferences in November 2023November 9, 2023 | benzinga.comInogen Stock (NASDAQ:INGN), Analyst Ratings, Price Targets, PredictionsNovember 8, 2023 | msn.comInogen (INGN) Q3 Earnings Miss Estimates, Revenues Down Y/YNovember 8, 2023 | finance.yahoo.comInogen, Inc. (NASDAQ:INGN) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | benzinga.comInogen: Q3 Earnings InsightsNovember 7, 2023 | finance.yahoo.comInogen Announces Third Quarter 2023 Financial ResultsNovember 5, 2023 | morningstar.comInogen Inc INGNOctober 16, 2023 | finance.yahoo.comHere's Why Inogen (INGN) Is a Great 'Buy the Bottom' Stock NowOctober 13, 2023 | finance.yahoo.comInogen (INGN) Loses -24.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerOctober 10, 2023 | finanznachrichten.deInogen Alliance: The Role of EHS in Workforce Mental Health ProgramsOctober 10, 2023 | finance.yahoo.comInogen to Report Third Quarter 2023 Financial Results on November 7, 2023September 19, 2023 | msn.comInogen (INGN) Completes Buyout Deal to Expand Product PortfolioSeptember 18, 2023 | markets.businessinsider.comInogen Closes Acquisition Of Physio-Assist SASSeptember 18, 2023 | finance.yahoo.comInogen Completes Acquisition of Physio-AssistSeptember 7, 2023 | markets.businessinsider.comInogen Names Mike Sergesketter As Interim CFO To Succeed Kristin CaltriderSeptember 7, 2023 | marketwatch.comInogen Chief Financial Officer Kristin Caltrider Resigns >INGNAugust 8, 2023 | msn.comJP Morgan Downgrades Inogen (INGN)See More Headlines Receive INGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INGN CUSIPN/A CIK1294133 Webwww.inogen.com Phone(805) 562-0500FaxN/AEmployees1,026Year Founded2001Price Target and Rating Average Stock Price Target$13.67 High Stock Price Target$26.00 Low Stock Price Target$7.00 Potential Upside/Downside+135.2%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($5.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,770,000.00 Net Margins-40.42% Pretax Margin-40.18% Return on Equity-30.65% Return on Assets-22.03% Debt Debt-to-Equity RatioN/A Current Ratio3.73 Quick Ratio3.33 Sales & Book Value Annual Sales$327.86 million Price / Sales0.41 Cash FlowN/A Price / Cash FlowN/A Book Value$12.98 per share Price / Book0.45Miscellaneous Outstanding Shares23,308,000Free Float23,159,000Market Cap$135.42 million OptionableOptionable Beta1.10 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Michael K. Sergesketter (Age 63)Interim Executive Vice President, Chief Financial Officer & Treasurer Comp: $227.53kDr. Stanislav Glezer M.D. (Age 50)MBA, Executive VP & CTO Comp: $575.8kMr. Jason Somer (Age 55)Executive VP, General Counsel & Corporate Secretary Comp: $409.92kMr. Kevin R. Smith (Age 52)President, CEO & Director Ms. Jennifer Yi BoyerExecutive VP & Chief Human Resources OfficerMr. Vijay PaliwalSenior Vice President of Enterprise EnablementMr. Matthew PigeonInvestor Relations OfficerMore ExecutivesKey CompetitorsAltitude AcquisitionNASDAQ:ALTUCollPlant BiotechnologiesNASDAQ:CLGNMilestone ScientificNYSE:MLSSEargoNASDAQ:EARJin Medical InternationalNASDAQ:ZJYLView All CompetitorsInstitutional OwnershipDeutsche Bank AGBought 2,584 shares on 11/24/2023Ownership: 0.060%Walleye Capital LLCSold 137,008 shares on 11/21/2023Ownership: 0.297%Jacobs Levy Equity Management Inc.Bought 15,471 shares on 11/17/2023Ownership: 1.713%Tudor Investment Corp Et AlBought 38,037 shares on 11/16/2023Ownership: 0.163%Toroso Investments LLCBought 7,339 shares on 11/15/2023Ownership: 0.078%View All Institutional Transactions INGN Stock Analysis - Frequently Asked Questions Should I buy or sell Inogen stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" INGN shares. View INGN analyst ratings or view top-rated stocks. What is Inogen's stock price target for 2024? 4 Wall Street analysts have issued twelve-month price objectives for Inogen's stock. Their INGN share price targets range from $7.00 to $26.00. On average, they expect the company's stock price to reach $13.67 in the next year. This suggests a possible upside of 135.2% from the stock's current price. View analysts price targets for INGN or view top-rated stocks among Wall Street analysts. How have INGN shares performed in 2023? Inogen's stock was trading at $19.71 on January 1st, 2023. Since then, INGN shares have decreased by 70.5% and is now trading at $5.81. View the best growth stocks for 2023 here. Are investors shorting Inogen? Inogen saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,550,000 shares, an increase of 52.0% from the October 31st total of 1,020,000 shares. Based on an average trading volume of 277,700 shares, the short-interest ratio is presently 5.6 days. View Inogen's Short Interest. When is Inogen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our INGN earnings forecast. How were Inogen's earnings last quarter? Inogen, Inc. (NASDAQ:INGN) announced its quarterly earnings data on Tuesday, November, 7th. The medical technology company reported ($1.97) earnings per share for the quarter, missing the consensus estimate of ($0.56) by $1.41. The medical technology company earned $84 million during the quarter, compared to the consensus estimate of $82.09 million. Inogen had a negative net margin of 40.42% and a negative trailing twelve-month return on equity of 30.65%. The firm's revenue was down 20.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.34) EPS. What guidance has Inogen issued on next quarter's earnings? Inogen updated its FY 2023 earnings guidance on Tuesday, September, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $315.00 million-$320.00 million, compared to the consensus revenue estimate of $316.73 million. What is Scott Wilkinson's approval rating as Inogen's CEO? 70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Inogen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX). Who are Inogen's major shareholders? Inogen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Fred Alger Management LLC (4.59%), Ameriprise Financial Inc. (2.88%), AQR Capital Management LLC (2.62%), Meros Investment Management LP (2.54%), Kent Lake Capital LLC (1.99%) and Jacobs Levy Equity Management Inc. (1.71%). Insiders that own company stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Holdings A/S Novo, Ray Benjamin M Anderson and Raymond Huggenberger. View institutional ownership trends. How do I buy shares of Inogen? Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:INGN) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inogen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.